Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens. EULAR has commissioned a task force to
Read Article
Links:
What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Read Article
A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.
Lancet reports that in a randomized, blinded, controlled trial, gabapentin failed to significantly lower pain scores in women with chronic pelvic pain, and was associated with higher adverse event rates compared to placebo.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Data from the Framingham Heart Study has shown that hip fracture incidence has decreased over time, probably resulting from improved lifestyle changes (less smoking and heavy drinking).
The incidence of hip fracture has been shown to be decreasing in the US, presumeably attributeable
Read Article
JAMA Internal Medicine reports on a controlled clinical trial of knee osteoarthritis patients wherein meloxicam responses were not significantly or clinically superior to placebo or CBT (after placebo).
Because of the uncertain benefits and safety of long-term NSAIDs,
Read Article
Comorbidities are highly prevalent in psoriatic disease. A recent study in Arthritis Research & Therapy suggests a high prevalence of sleep disturbances, fatigue, and anxiety/depression in psoriatic arthritis (PsA) that is unrelated to skin disease musculoskeletal (MSK)
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy in a new guideline for treating acute, non-low back pain from musculoskeletal injuries in outpatient settings.
The clinical guide, released by the American College of Physicians (ACP) and the
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
